{"id":"NCT01440387","sponsor":"GlaxoSmithKline","briefTitle":"A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older","officialTitle":"A Phase IIIA Study of Immunogenicity and Safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-30","primaryCompletion":"2011-10-22","completion":"2011-10-22","firstPosted":"2011-09-26","resultsPosted":"2013-11-19","lastUpdate":"2018-09-07"},"enrollment":112,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"FLULAVALÂ® QUADRIVALENT","otherNames":[]}],"arms":[{"label":"FLULAVAL QUADRIVALENT Adult Group","type":"EXPERIMENTAL"},{"label":"FLULAVAL QUADRIVALENT Elderly Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline (GSK) Biologicals' investigational quadrivalent split virion influenza vaccine FLU-Q-QIV in adults 18 years of age and older.","primaryOutcome":{"measure":"Humoral Immune Response in Terms of Hemagglutination Inhibition (HI) Antibodies Against Each of the 4 Vaccine Influenza Strains.","timeFrame":"At Day 0 and Day 21","effectByArm":[{"arm":"FLULAVAL QUADRIVALENT Adult Group","deltaMin":130.4,"sd":null},{"arm":"FLULAVAL QUADRIVALENT Elderly Group","deltaMin":57.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":19},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":["24606983"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Pain","Muscle pain","Headache","Fatigue","Sore throat"]}}